BREAKING! John Hopkin’s Study Alarmingly Discovers That Up To 43 Percent Of Post-COVID-19 Individuals Have Persistent Cardiovascular Issues!

A new study by researchers from Johns Hopkins University-USA has alarmingly discovered that up to 43% of post-COVID individuals have persistent cardiovascular issues! Researchers from the University of Wollongong-Australia also collaborated in the study.


 
The study team initially planned to examine risk factors for cardiac-related PASC in community-dwelling adults after acute coronavirus disease 2019 (COVID-19) infection.
 
The study team performed a cross-sectional analysis among adults who tested positive for COVID-19. Outcomes were self-reported cardiac-related PASC.
 
The researchers conducted stepwise multivariable logistic regression to assess association between the risk factors (existing cardiovascular disease, pre-existing conditions, days since positive test, COVID hospitalization, age, sex, education, income) and cardiac-related PASC.
 
In a sample of 442 persons, mean (SD) age was 45.4 (16.2) years, 71% were female, 13% were black, 46% had pre-existing conditions, 23% had CV risk factors, and 4% had CV illness (CVD).
 
Shockingly, prevalence of cardiac PASC were 43% and newly diagnosed cardiac conditions was 27%. The odds for cardiac-related PASC were higher among persons with underlying pre-existing conditions (adjusted odds ratio aOR: 2.00, 95% CI:1.28-3.10) and among those who were hospitalized (aOR: 3.03, 95%CI:1.58-5.83).
 
The study findings alarmingly showed that more than a third of persons with COVID-19 reported cardiac-related PASC symptoms. Underlying CVD, pre-existing diseases, age, and COVID-19 hospitalization are possible risk factors for cardiac-related PASC symptoms. COVID-19 may exacerbate CV risk factors and increase risk of complications.
 
The study findings were published on a preprint server and are currently being peer reviewed.
 
Thailand Medical News has been warning that excess death rates globally are rising with heart failure that are related to COVID-19 being a major contributor.
 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19, is a deadly beta-coronavirus that primarily infects the human respiratory tract. Besides inducing acute respiratory symptoms, the virus also infects other vital organs and causes long-term complications, which is commonly known as long-COVID.
 
PASC (Post-Acute Sequelae of SARS CoV-2 infection) or long-COVID symptoms can persist for several weeks after the resolution of acute infection.
 
Interestingly among various long-COVID symptoms, a considerably high prevalence of cardiovascular complications has been observed in COVID-19 recovered individuals. Studies have shown that cardiovascular symptoms can persist for about 6 months in COVID-recovered individuals who had been hospitalized during the acute infection phase.
 
Aside from persistent symptoms, new-onset cardiovascular complications have also been noticed in both hospitalized and non-hospitalized COVID-recovered individuals. These observations highlight the risk of cardiovascular morbidity and disability among patients with long-COVID.
 
This is the first study to date that has determined the prevalence and risk factors of long-term cardiovascular sym ptoms in community-dwelling adults with prior SARS-CoV-2 infection.    
 
The research population included a total of 442 adults who previously had laboratory-confirmed SARS-CoV-2 infection.
 
The study used self-reported surveys to collect baseline information on sociodemographic factors, COVID-19-related parameters, pre-existing health conditions, persistent cardiovascular symptoms, new-onset cardiovascular complications, fatigue, and overall wellbeing.
 
The key primary outcome of the study was self-reported cardiovascular symptoms that were present three weeks after a positive COVID-19 test as well as at the time of survey enrollment.
 
Furthermore, self-reported information on new-onset cardiovascular complications was collected from the participants.
 
Alarmingly, the prevalence of post-acute cardiovascular symptoms was estimated to be 43% in the study population.
 
It was also found among these participants that only 12% reported being hospitalized during the acute phase of SARS-CoV-2 infection.
 
This means that asymptomatic and mild-symptomatic SARS-CoV-2 infected individuals are also prone to developing cardiovascular issues after COVID-19 ‘recovery’.
 
Significantly, the average duration of symptom continuance since the detection of primary infection was 12 months.
 
It should be noted that among long-term cardiovascular symptoms, the most frequent was heart palpitation, followed by tachycardia, feeling faint, persistent chest pain, and sharp chest pain. Regarding other general symptoms, the most common symptom was fatigue, followed by joint pain, muscle pain, breathing difficulty, and activity intolerance.
 
It was also discovered that fatigue was more commonly observed among participants with post-acute cardiovascular symptoms. Similarly, a lower functioning of mental and physical health was observed in these participants.
 
Also, worryingly, new-onset cardiovascular complications were observed in about 27% of participants after recovery from acute infection. The most prevalent complication was tachycardia, followed by hypertension and postural orthostatic tachycardia syndrome. 
 
Also, alarming, a relatively higher prevalence of tachycardia and myocarditis was observed among participants who had recovered from COVID-19 more than 18 months ago.
 
The study participants with pre-existing cardiovascular disease or other health conditions showed a significantly higher risk of developing long-term post-COVID cardiovascular symptoms. In addition, increasing age and COVID-19-related hospitalization were identified as potent risk factors for long-COVID.
 
Importantly, the study reveals a high prevalence (43%) of long-term cardiovascular symptoms in community-dwelling adults with previous SARS-CoV-2 infection. Also, the prevalence of new-onset cardiovascular complications including hypertension and tachycardia was 27% in the study population.
 
The study also identifies that pre-existing cardiovascular disease or other health conditions, older age, and COVID-19-related hospitalization serve as potent risk factors for post-acute cardiovascular symptoms.


 
Thailand Medical News would like to add that despite the high incidence of cardiovascular issues in many SARS-CoV-2 infected individuals, we have certain stupid and incompetent doctors in Thailand and even also certain groups associated with the WHN advocating the usage of fluvoxamine to treat  both COVID-19 and also Long COVID despite the drug being able to induce arrythmia and other heart issues.
https://www.jstage.jst.go.jp/article/jts/40/1/40_33/_article
 
https://www.jpeds.com/article/S0022-3476(20)30850-7/fulltext
 
Two other charlatans, one a stupid arrogant female American ‘virologist’ now in Canada and a Muslim male gastroenterologists working in America have been trying to further the agenda of promoting Fluvoxamine and other SSRIs to treat COVID-19 data despite the mounting data that it does not really work and that is no better than a placebo. (Though the new data shows that it is more of a nocebo!)
 
Even then, some of these studies did not reflect the deaths among the research participants due to heart failure triggered by arrythmia. In one meta-analysis of comparing the three drugs – Fluvoxamine, Paxlovid and Molnupiravir, only Fluvoxamine reflected the most cases of deaths (and in all cases heart failures!)
https://www.tandfonline.com/doi/pdf/10.1080/07853890.2022.2034936
 
In fact a study in December 2021 already highlighted that Fluvoxamine is not effective in preventing disease severity. 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745642/

The Omicron and worst the BA.2, BA.4 and BA.5 variants and emerging subvariants are found to be able to suppress many interferon releases and functions and also disable the human host immune responses hence accounting for its mild or asymptomatic manifestations during the initial stages of infection.
 
These variants and their emerging subvariants are adapt at replicating very fast in the other parts of the human host including the lower respiratory tract and also building up huge reservoirs in the heart, liver, kidneys, CNS system, gastrointestinal and male reproductive organs. These indirectly affects the heart in a multitude of ways and with stupid individuals taking Fluvoxamine that is already known to cause arrythmia, they are actually increasing the risk of heart failure! https://www.goodrx.com/classes/ssris/ssris-what-you-should-know-side-effects
 
https://www.jstage.jst.go.jp/article/jts/40/1/40_33/_article
 
It is even worse for those with SCN5A mutations and suffer from Brugada syndrome, they will have a high risk of death if they have COVID and are also given Fluvoxamine. 
https://academic.oup.com/europace/article/12/2/282/430346
 
Also, if combined with certain supplements, the risk of arrythmia and heart failure is greatly increased!
 
Fluvoxamine despite having two pathways to work as an antiviral against certain other viruses, does not work that way with the SARS-CoV-2 virus
 
It does not serve in any way as a prophylactic against SARS-CoV-2 infection despite a lot of stupids taking it.
 
We have also uncovered other dangers ie hyponatremia etc associated with taking fluvoxamine in the current BA.2, BA.4 and BA.5 prevalence.
 
It has also been uncovered that the BA.2, BA.4 and BA.5 variants and also subvariants due to their nature of also binding with other host receptors besides the ACE2 receptors are indirectly able to affect and dysregulate a gene called MAPRE2 that plays a very critical role in the heart muscles. Treating people already with current SARS-CoV-2 infections with fluvoxamine can actually literally trigger a heart failure!
 
For more on SARS-CoV-2 Induced Heart Issues, keep on logging to Thailand Medical News.